| HRA006326
(Controlled Access)
|
Background: Multiple myeloma (MM) is a malignant neoplasm of plasma cells leading to bone destruction and marrow failure. Prognosis and management of MM rely on cytogenetic determination of copy number abnormalities (CNAs). Nevertheless, chromosome abnormality analysis is difficult due to the presence of few plasma cells and their low proliferative activity. Conclusions: Based on its clinical performance, LeukoPrint can be regarded as an automated, convenient and cost-effective approach to describe genomic CNA profiles and considered to complement conventional karyotyping and FISH in the analysis of CNAs for MM patients. LeukoPrint can also use peripheral blood for CNA analysis, which could be utilized for monitoring the dynamic change of molecular responses in MM patients during the course of treatment. |
